Chimeric Therapeutics Limited · ASX:CHM
Chimeric Therapeutics — Shareholder Meeting (November 2021)
18 slides from Chimeric Therapeutics's shareholder meeting presentation, Nov 22, 2021
Slide 1: Annual General Meeting Corporate Update
For personal use only Annual General Meeting Corporate Update I November 22, 2021
Slide 2: Corporate Snapshot
CHIMERIC THERAPEUTICS CORPORATE SNAPSHOT For personal use only The ASX leader in cell therapy as the only clinical Founded in 2020 and listed on the ASX (CHM) in stage cell therapy company January 2021 with an oversubscribed raise of $35M Lead asset, CHM 1101 (CLTX CAR T) advancing in 0.4 0.37 0.35
Slide 3: Our Mission: To Bring the Promise of Cell Therapy to Life
OUR MISSION To Bring the Promise of Cell Therapy to Life For personal use only Traditional drug development focuses on delaying disease progression- not on a cure. We believe that novel cellular therapies have the promise to cure cancer. “These are patients with an abysmal prognosis, really without
Slide 4: Cell Therapy Investment Landscape
CELL THERAPY INVESTMENT LANDSCAPE Cell therapy is the most active investment The global market for cell therapies In the past 18-24 months, 16 of the largest For personal use only sector in biotech today with ~$20B in is estimated to reach between pharmaceutical companies have added cell and financi
Slide 5: Chimeric Portfolio Development Strategy
CHIMERIC PORTFOLIO DEVELOPMENT STRATEGY Focused on building a diversified cell therapy pipeline with cutting edge innovation For personal use only Novel Designs Alternative T Cells NK Cells Cell Types Individualized Alternative Off the Shelf (autologous) Cell Sources (allogeneic)
Slide 6: Chimeric Pipeline Novel CAR T Cell Therapies
CHIMERIC PIPELINE 2 NOVEL CAR T CELL THERAPIES For personal use only Ongoing phase 1 clinical trial 2 additional phase 1 clinical trials planned for 2022 Development across 7 different types of cancer
Slide 7: What Is CAR T Cell Therapy?
WHAT IS CAR T CELL THERAPY? Cell therapy is the transfer of live cells into a patient to treat or cure a disease. For personal use only Chimeric Antigen Receptor T (CAR T) Cell Therapy is a type of cell therapy that modifies a patient’s own immune cells (T-cells) to use directly against their cancer
Slide 8: CHM 1101: Chlorotoxin (CLTX) CAR T
CHM 1101: CHLOROTOXIN (CLTX) CAR T For personal use only CHM 1101 (CLTX CAR T) was designed and studied preclinically in glioblastoma, one of the most lethal types of cancer. Patients with glioblastoma have an expected survival of ~12 months and only 38% survive more than one year. CHM 1101 uniquely
Slide 9: CHM 1101 (CLTX CAR T) Ongoing Phase 1 Clinical Trial
CHM 1101 (CLTX CAR T) Ongoing Phase 1 Clinical Trial Advancing Towards Higher Dose Levels For personal use only Primary Objective: To assess the safety of CLTX CAR T cells and to determine the maximum tolerated dose schedule and a recommended Phase 2 dosing plan Phase 1 Clinical Trial Design: 4 dose
Slide 10: CHM 1101 (CLTX CAR T) Positive Initial Phase 1 Clinical Data
CHM 1101 (CLTX CAR T) Positive Initial Phase 1 Clinical Data For personal use only 75% Disease Control Rate (DCR) Efficacy CLTX CAR T demonstrated a 75% Disease Control Rate in the 1st dose level Safety No Dose Limiting Toxicities CLTX CAR T cells were generally well tolerated with no dose limiting
Slide 11: CHM 1101 (CLTX CAR T) SNO Presentation Data Update
CHM 1101 (CLTX CAR T) SNO Presentation Data Update For personal use only (Nov 19, 2021) 75% Disease control rate (DCR) Efficacy with up to 8 weeks of durability Regional control of tumour recurrence where Efficacy CLTX CAR T cells were infused No dose limiting toxicities and no Safety cytokine relea
Slide 12: CHM 1101 (CLTX CAR T) Clinical Development Program
CHM 1101 (CLTX CAR T) Clinical Development Program For personal use only FDA clearance for Chimeric CLTX IND in August 2021 enables accelerated and expanded clinical development in 2022 Preclinical Phase 1 CLTX CAR T City of Hope Clinical Trial Site Glioblastoma Clinical Trial Clinical Trial Site. #
Slide 13: CHM 2101 (CDH17 CAR T): Promise for Gastrointestinal Cancers
CHM 2101 (CDH17 CAR T) PROMISE FOR GASTROINTESTINAL CANCERS For personal use only Exclusive Chimeric licensing from the University of Pennsylvania • Competitive licensing process for the novel 3rd generation CDH17 CAR T from world renowned cell therapy centre CDH17 CAR T Dramatic Preclinical Efficac
Slide 14: CDH17 CAR T: Accelerating Development Towards the Clinic
CDH17 CAR T ACCELERATING DEVELOPMENT TOWARDS THE CLINIC For personal use only Completed critical first milestone • CDH17 viral vector manufacturing • CDH17 clinical manufacturing on path to clinical manufacturing readiness readiness in 2022 • CDH17 preclinical data in neuroendocrine (NET) and • CH
Slide 15: Chimeric Ongoing Pipeline Development
CHIMERIC ONGOING PIPELINE DEVELOPMENT Further pipeline development is a key focus for 2021-2022 For personal use only Novel Designs T Cells Individualized NK Cells (autologous) CLTX CLTX CDH17 Phase 1 CAR T CAR T CAR T Off the Shelf ongoing in brain cancer Phase 1 Ongoing Phase 1 Planned 2022 (allog
Slide 16: Chimeric Management Team
CHIMERIC MANAGEMENT TEAM GLOBAL EXPERTS IN CELL THERAPY DEVELOPMENT & COMMERCIALIZATION For personal use only Development of over 25 CELL THERAPIES including Jennifer Dr Eliot Dr Li Dr Syed 4/5 CHOW BOURK REN OF THE RIZVI Chief Operating VP, Business and VP, Technical FDA-APPROVED Chief Medical Offi
Slide 17: The ASX Leader in Cell Therapy
THE ASX LEADER IN CELL THERAPY For personal use only Two novel cell therapy assets from world renowned institutions, University of Pennsylvania and City of Hope Potential Value Realization Pathways CLTX CAR T current phase 1 clinical trial advancing in glioblastoma with encouraging early data; 2
Slide 18: Contact Information
For personal use only CONTACT INFORMATION Jennifer Chow Chief Executive Officer Chimeric Therapeutics Ltd Cell: +1 908-723-8387 jchow@chimerictherapeutics.com Paul A. Hopper Executive Chairman Chimeric Therapeutics Ltd Cell: +61 406671515 paulhopper@lifescienceportfolio.com 18.
Chimeric Therapeutics — Shareholder Meeting (November 2021) on 6ix